Compare DAKT & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DAKT | JANX |
|---|---|---|
| Founded | 1968 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Office Equipment/Supplies/Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 872.1M | 790.3M |
| IPO Year | 1994 | 2021 |
| Metric | DAKT | JANX |
|---|---|---|
| Price | $27.22 | $13.24 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 12 |
| Target Price | N/A | ★ $57.36 |
| AVG Volume (30 Days) | 547.3K | ★ 1.7M |
| Earning Date | 03-04-2026 | 03-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $770,283,000.00 | $10,000,000.00 |
| Revenue This Year | $13.76 | N/A |
| Revenue Next Year | $7.35 | N/A |
| P/E Ratio | $188.15 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.24 | $12.12 |
| 52 Week High | $27.63 | $38.42 |
| Indicator | DAKT | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 83.18 | 42.38 |
| Support Level | $25.69 | $12.74 |
| Resistance Level | $24.96 | $13.79 |
| Average True Range (ATR) | 1.19 | 0.68 |
| MACD | 0.32 | 0.10 |
| Stochastic Oscillator | 97.46 | 42.70 |
Daktronics Inc designs and manufactures electronic scoreboards, programmable display systems, and large-screen video displays for sporting, commercial, and transportation applications. It is engaged in a full range of activities: marketing and sales, engineering and product design and development, manufacturing, technical contracting, professional services, and customer service and support. The company offers a complete line of products, from small scoreboards and electronic displays to large multimillion-dollar video display systems as well as related control, timing, and sound systems. The company has five reportable segments: Commercial, Live Events, High School Park and Recreation, Transportation, and International. The company makes the majority of its revenue from Live events.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.